AtomVie Unveils State‑of‑the‑Art Radiopharmaceutical Manufacturing Hub in Hamilton

On September 5, 2026, AtomVie Global Radiopharma threw open the doors of its brand‑new manufacturing complex on Aeropark Boulevard in Hamilton, Ontario, and the excitement in the room was palpable.

The $160 million investment adds up to a 72,300‑square‑foot, purpose‑built site that, by the numbers, is the biggest single‑location CDMO dedicated to radiopharmaceuticals ever built in North America. In plain English, it means a ten‑fold jump in the company’s production capacity and the ability to move from early‑stage development straight through to full commercial output under one roof.

What really sets the facility apart is its flexibility. Designed for low‑to‑high‑throughput runs, the space can be reconfigured on the fly to match the exact needs of each client’s pipeline. Think of it as a laboratory that grows with you, from the first milligram of a new tracer all the way to the megabatches required for worldwide distribution.

AtomVie isn’t a brand‑new kid on the block; it spun out of the Centre for Probe Development and Commercialization (CPDC) at McMaster University, a hub that was created to cement Canada’s role as a leader in nuclear‑medicine innovation. The Hamilton plant is part of a broader plan to expand the team to more than 200 staff members by the end of 2026, bringing together scientists, engineers, and support staff who share a common purpose.

That purpose is backed by a solid track record. Over the past decade the company has helped launch more than 70 clinical development and technology‑transfer programs, produced in excess of 1,000 cGMP batches and delivered over 4,400 cGMP doses to patients in 28 countries across six continents – all with a delivery success rate north of 99 %.

“This Grand Opening represents the next chapter of AtomVie's journey and a proud milestone for Canadian innovation in nuclear medicine,” said Bruno Paquin, AtomVie’s CEO. “Our new purpose‑built facility amplifies a proven track record of reliable global delivery and deep scientific expertise, enabling us to support the development and commercialization of our partners’ pipelines. Above all, it advances our purpose of transforming patients’ lives by delivering high‑quality radiopharmaceuticals to those who need them, all around the world.”

Kevin McNeill, chair of the board, added, “The inauguration reflects the discipline and dedication of the AtomVie team and the confidence of the partners who have supported our growth. This facility cements AtomVie's status as a leading radiopharmaceutical CDMO, now built at commercial scale to serve partners with the reliability the field requires.”

The celebration drew government officials, existing and prospective clients, and members of the broader radiopharma community. Attendees toured the clean‑room suites, watched demonstrations of the automated synthesis modules, and got a first‑hand look at how the new plant will help push the next generation of precision cancer therapies from bench to bedside.

About AtomVie Global Radiopharma: AtomVie is a worldwide CDMO that offers a full suite of scientific, technical, regulatory, quality and logistics services for radiopharmaceuticals from Phase I through Phase III clinical studies and commercial launch. Its client base spans more than 28 countries, and the company continues to expand its capabilities to meet the growing demand for targeted nuclear‑medicine treatments. For more information, visit https://www.atomvie.com.